While the pharma industry hasn’t yet fully embraced the potential of digital health solutions, it’s become clear that a strong digital health strategy can play a pivotal role in achieving long-term success.
This presents a dilemma for pharma companies: whether to build, partner, or buy, when it comes to creating and maintaining a digital health solution.
In this whitepaper, experts from S3 Connected Health, Takeda, Pfizer, and Novartis debate the merits of each option and what they might entail for a pharma company, discussing questions including:
File Size: 2.5 MB